Lab
Empower Genomics Corp
Empower Genomics Corp was paid $252K by Medicaid between Nov 2021 and Jan 2024, across 7 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 32% of everything it billed.
33Billing provider infoEMPOWER GENOMICS CORP
ESCONDIDO, CA 92025
ESCONDIDO, CA 92025
33aNPI1982360004assigned 11/12/2021
33bProvider typeClinical Medical Laboratory
28Total paid$252K
24GClaims9,233
24DCodes billed7
24AFirst – last monthNov 2021 – Jan 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#275 of 561
Median peer was paid$222K
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 404 | $10K | |
| 2022 | 5,195 | $139K | |
| 2023 | 3,604 | $102K | |
| 2024incomplete | 30 | $1K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 32% | 2,890 | 1,641 | $82K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 32% | 1,254 | 593 | $81K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 29% | 3,441 | 1,791 | $73K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.4% | 207 | 186 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.6% | 211 | 106 | $4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | <1% | 1,026 | 1,012 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 204 | 99 | $2K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCOLLUM, KYLE (CFO)
| Provider | Location | Paid |
|---|---|---|
| IV Services LLC | Metairie, LA | $354K |
| Pala Diagnostics, LLC | San Diego, CA | $79K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.